Logo for Lexeo Therapeutics Inc

Lexeo Therapeutics Investor Relations Material

Latest events

Logo for Lexeo Therapeutics Inc

Study Update

Lexeo Therapeutics
Logo for Lexeo Therapeutics

Study Update

15 Jul, 2024
Logo for Lexeo Therapeutics

Corporate Presentation

3 Jun, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Lexeo Therapeutics Inc

Access all reports
Lexeo Therapeutics Inc. operates as a clinical-stage genetic medicine company focused on hereditary and acquired diseases. The company is advancing a portfolio of gene therapy candidates, including LX2006 for Friedreich's ataxia cardiomyopathy, LX2020 for arrhythmogenic cardiomyopathy, LX2021 for DSP cardiomyopathy, and LX2022 for hypertrophic cardiomyopathy caused by TNNI3 mutations. Additionally, Lexeo Therapeutics is developing therapies for APOE4 homozygous conditions and CLN2 Batten disease, among others, utilizing its AAVrh10-based gene therapy platform. The company is headquartered in New York, New York, and its shares are listed on the Nasdaq.